<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124419</url>
  </required_header>
  <id_info>
    <org_study_id>DO608715A</org_study_id>
    <nct_id>NCT04124419</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Combined EMS and RF Treatments</brief_title>
  <official_title>Baseline Controlled Study to Evaluate the Safety and Efficacy of Combined EMS and RF Treatments for Non-Invasive Circumference Reduction and Skin Tightening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the safety and efficacy of the Evolve device&#xD;
      utilizing the Ti10 and Tone applicators for abdominal non-invasive circumference reduction&#xD;
      and skin tightening&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Actual">May 19, 2021</completion_date>
  <primary_completion_date type="Actual">May 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in circumference reduction</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>statistical difference in circumference reduction between Control (baseline measurement) and three points of follow-up measurement: 4 weeks (1Month) 12 weeks (3Month) and 24 weeks (6 months) following the last Tx session.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in skin appearance</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>Improvement in skin appearance comparing pre and at 1, 3 months and 6 months post last treatment photographs (as assessed by blinded investigators):&#xD;
Success is defined by correct identification of the pre and post-treatment photos as demonstrated in at least 70% or greater of patients completed the treatment at 1 month, 3 months, and 6 months post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in abdomen area appearance assessed by 3D Photographic analysis</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>3D Photographic analysis will be conducted using QuantifiCare System at follow up visits and compared to the baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in abdomen area appearance assessed by Investigator</measure>
    <time_frame>1 month, 3 month, 6 months</time_frame>
    <description>- Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Improvement assessment</measure>
    <time_frame>1 Month, 3 Months, 6 Months</time_frame>
    <description>Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows:&#xD;
4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction assessment</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows:&#xD;
+2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of comfort</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Subject assessment of comfort will be filled out by subjects using a 5-point Likert scale, as follows:&#xD;
+2 = Very comfortable; +1 = Comfortable; 0 = Indifferent; -1 = uncomfortable; -2 = Pain.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Non-invasive Circumference Reduction</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with Evolve System</intervention_name>
    <description>EMS and RF Treatment</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Signed informed consent to participate in the study.&#xD;
&#xD;
          -  Female and male subjects,18 - 65 years of age at the time of enrolment&#xD;
&#xD;
          -  BMI≤ 30&#xD;
&#xD;
          -  If female, not pregnant, lactating and must be either post-menopausal, surgically&#xD;
             sterilized, or using a medically acceptable form of birth control at least 3 months&#xD;
             prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods&#xD;
             with spermicide or abstinence).&#xD;
&#xD;
          -  In addition, negative urine pregnancy test as tested before each treatment and at the&#xD;
             last visit for women with childbearing potential (e.g. not menopause).&#xD;
&#xD;
          -  General good health confirmed by medical history and skin examination of the treated&#xD;
             area.&#xD;
&#xD;
          -  Willing to have photographs and images taken of the treated areas to be used&#xD;
             de-identified in evaluations, publications and presentations.&#xD;
&#xD;
          -  The patients should be willing to comply with the study procedure and schedule,&#xD;
             including the follow up visit, and will refrain from using any other aesthetic&#xD;
             treatment methods for the last 6 months and during the entire study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pacemaker or internal defibrillator, or any other metallic or electronic implant&#xD;
             anywhere in the body.&#xD;
&#xD;
          -  Permanent implant in the treated area such as metal plates, screws and metal piercing,&#xD;
             silicone implants or an injected chemical substance, unless deep enough in the&#xD;
             periosteal plane.&#xD;
&#xD;
          -  Intra-dermal or superficial sub-dermal areas that have been injected with&#xD;
             HA/collagen/fat injections or other augmentation methods with bio-material during last&#xD;
             6 months.&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or pre-malignant moles.&#xD;
&#xD;
          -  Severe concurrent conditions, such as cardiac disorders, sensory disturbances,&#xD;
             epilepsy, uncontrolled hypertension, and liver or kidney diseases.&#xD;
&#xD;
          -  Pregnancy and nursing.&#xD;
&#xD;
          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV,&#xD;
             autoimmune disorders or use of immunosuppressive medications.&#xD;
&#xD;
          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and&#xD;
             hormonal virilization.&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and&#xD;
             rash.&#xD;
&#xD;
          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin.&#xD;
&#xD;
          -  History of bleeding coagulopathies, or use of anticoagulants in the last 10 days.&#xD;
&#xD;
          -  Any surgical procedure in the treatment area within the last 6 months or before&#xD;
             complete healing.&#xD;
&#xD;
          -  Having received treatment with light, laser, RF, or other devices in the treated area&#xD;
             within 3 months, or before complete healing.&#xD;
&#xD;
          -  Use of Isotretinoin (Accutane®) within 6 months prior to treatment.&#xD;
&#xD;
          -  As per the practitioner's discretion, refrain from treating any condition which might&#xD;
             make it unsafe for the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Avance Plastic Surgery Institute</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BodySculpt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

